Nothing Special   »   [go: up one dir, main page]

Broersen et al., 2010 - Google Patents

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Broersen et al., 2010

View HTML @Full View
Document ID
11079304572580158096
Author
Broersen K
Rousseau F
Schymkowitz J
Publication year
Publication venue
Alzheimer's research & therapy

External Links

Snippet

Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimer's disease, many researchers refocused on detecting a specific molecular assembly of defined size thatis the …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701

Similar Documents

Publication Publication Date Title
Broersen et al. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
Sinha et al. A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity
Adegbuyiro et al. Proteins containing expanded polyglutamine tracts and neurodegenerative disease
Hatami et al. Familial Alzheimer’s disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-β peptide
Hatters et al. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils
Paula-Lima et al. Human apolipoprotein A–I binds amyloid-β and prevents Aβ-induced neurotoxicity
Johansson et al. Physiochemical characterization of the Alzheimer's disease‐related peptides Aβ1–42Arctic and Aβ1–42wt
Jeganathan et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments
Hubin et al. Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Pillay et al. Amylin uncovered: a review on the polypeptide responsible for type II diabetes
Rahimi et al. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders
Jayaraman et al. Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties
Vosough et al. Characterization of homogeneous and heterogeneous amyloid-β42 oligomer preparations with biochemical methods and infrared spectroscopy reveals a correlation between infrared spectrum and oligomer size
Mannini et al. Stabilization and characterization of cytotoxic Aβ40 oligomers isolated from an aggregation reaction in the presence of zinc ions
Amijee et al. The N-methylated peptide SEN304 powerfully inhibits Aβ (1–42) toxicity by perturbing oligomer formation
Wang et al. Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
Eschmann et al. Tau aggregation propensity engrained in its solution state
Wetzel Exploding the repeat length paradigm while exploring amyloid toxicity in Huntington’s disease
Foley et al. Trapping and characterization of nontoxic Aβ42 aggregation intermediates
Adhikari et al. Acetylation of Aβ42 at lysine 16 disrupts amyloid formation
Meng et al. Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation
Sedighi et al. SUMOylation prevents huntingtin fibrillization and localization onto lipid membranes
Levy et al. Huntingtin’s N-terminus rearrangements in the presence of membranes: A joint spectroscopic and computational perspective
O’Malley et al. The aggregation paths and products of Aβ42 dimers are distinct from those of the Aβ42 monomer
Banerjee et al. Nanoscale infrared spectroscopy identifies structural heterogeneity in individual amyloid fibrils and prefibrillar aggregates